This compound emulates the inhibitory effects of somatostatin on hormone release, including growth hormone and insulin-like growth factor-I (IGF-I), positioning it as a key therapeutic agent in the management of acromegaly and certain gastroenteropancreatic neuroendocrine tumours (GEP-NETs) [130]. The gene discussed is IGF1; the disease is digestive system neuroendocrine tumor, grade 1/2.